These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 34562067)

  • 1. Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers.
    Wu X; Feng S; Zhang J; Zhang W; Zhang Y; Zhu M; Triyatni M; Zhao N; Bo Q; Jin Y
    Clin Transl Sci; 2022 Jan; 15(1):195-203. PubMed ID: 34562067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants.
    Feng S; Gane E; Schwabe C; Zhu M; Triyatni M; Zhou J; Bo Q; Jin Y
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.
    Yuen MF; Zhou X; Gane E; Schwabe C; Tanwandee T; Feng S; Jin Y; Triyatni M; Lemenuel-Diot A; Cosson V; Xue Z; Kazma R; Bo Q
    Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):723-732. PubMed ID: 34237271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti-Hepatitis B Virus Drug.
    Cosson V; Feng S; Jaminion F; Lemenuel-Diot A; Parrott N; Paehler A; Bo Q; Jin Y
    Clin Pharmacol Ther; 2021 Apr; 109(4):1081-1091. PubMed ID: 33523474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
    Chen X; Shen G; Jiang J; Liu H; Hu K; Darstein C; Lasher J; Hu P
    Clin Ther; 2014 Aug; 36(8):1196-210. PubMed ID: 25012727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
    Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
    Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
    Li C; Wu M; Zhang H; Mai J; Yang L; Ding Y; Niu J; Mao J; Wu W; Zhang D; Tang Y; Yan W
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0122021. PubMed ID: 34280012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.
    Kakuda TN; Yogaratnam JZ; Westland C; Gane EJ; Schwabe C; Vuong J; Patel M; Snoeys J; Talloen W; Lenz O; Fry J; Chanda S; van Remoortere P
    Antivir Ther; 2021; 26(1-2):13-24. PubMed ID: 35485346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
    McClure MW; Berliba E; Tsertsvadze T; Streinu-Cercel A; Vijgen L; Astruc B; Patat A; Westland C; Chanda S; Zhang Q; Kakuda TN; Vuong J; Khorlin N; Beigelman L; Blatt LM; Fry J
    PLoS One; 2018; 13(10):e0204974. PubMed ID: 30325939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
    Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
    Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.
    Zhao N; Xie R; Zhao X; Zhao H; Jia B; Zhang Y; Luo L; Huang Z; Li J; Wang X; Yan H; He B; Xie H; Ren Q; Cui Y
    Clin Drug Investig; 2019 Jul; 39(7):671-681. PubMed ID: 31079356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.
    Schluep T; Lickliter J; Hamilton J; Lewis DL; Lai CL; Lau JY; Locarnini SA; Gish RG; Given BD
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):350-362. PubMed ID: 27739230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
    Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
    Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.
    Menon RM; Klein CE; Podsadecki TJ; Chiu YL; Dutta S; Awni WM
    Br J Clin Pharmacol; 2016 May; 81(5):929-40. PubMed ID: 26710243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A First-in-Human Safety, Tolerability, and Pharmacokinetics Study of Benapenem in Healthy Chinese Volunteers.
    Zhao CY; Lv Y; Zhu Y; Wei MJ; Liu MY; Ji XW; Kang ZS; Xia YH; Tian JH; Ma Y; Liu Y
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.
    Liu Y; Tan Y; Wei G; Lu Z; Liu Y; Yang B; Hui AM; Li K
    Pulm Pharmacol Ther; 2022 Jun; 73-74():102132. PubMed ID: 35595003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
    Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
    Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.
    Nations KR; Bursi R; Dogterom P; Ereshefsky L; Gertsik L; Mant T; Schipper J
    Drugs R D; 2012 Sep; 12(3):127-39. PubMed ID: 22852579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.